|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Investment securities available for sale, net of allowance for credit losses of $0 at March 31, 2025 and December 31, 2024 | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Investment securities available-for-sale, net of allowance for credit losses of $0 at June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Loans, less allowance for credit losses of $19,740 at June 30, 2026 and $19,959 at December 31, 2025 | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Right-of-use assets | ||||||||||||||||||||
| Other real estate owned | ||||||||||||||||||||
| Bank owned life insurance | ||||||||||||||||||||
| Core deposit intangible | ||||||||||||||||||||
| Goodwill recognized | ||||||||||||||||||||
| Accrued interest receivable and other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Non-interest bearing | ||||||||||||||||||||
| Interest bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Repurchase agreements | ||||||||||||||||||||
| Lease liabilities | ||||||||||||||||||||
| Accrued interest payable and other liabilities | ||||||||||||||||||||
| Borrowings | ||||||||||||||||||||
| Junior subordinated deferrable interest debentures | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ equity: | ||||||||||||||||||||
| Serial preferred stock - no par value; 10,000,000 shares authorized; none outstanding | ||||||||||||||||||||
| Common stock, no par value; 22,500,000 shares authorized; issued and outstanding – 6,963,616 shares at June 30, 2026 and 6,958,814 at December 31, 2025 | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss, net | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
